Investigational drug · Phase 3
HRS-7058
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
7
Any phase or sponsor naming "HRS-7058"
First trial start
2025
Apr 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-7058", any sponsor or status.
Conditions studied
As listed on its trial records.
- KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
- Solid Tumors
- Pancreatic Cancer
- Resectable Non-small Cell Lung Cancer
- Advanced Malignant Tumour
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-7058" as an intervention, largest first.
- A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard TreatmentPivotal-lookingNot yet recruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07601048 · 450 participants (planned) · Start Jun 2026 · Primary completion May 2028
Drug: HRS-7058; Fulzerasib Tablets and 2 more · For: KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
Sites: Tianjin, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06915142 · 300 participants (planned) · Start Apr 28, 2025 · Primary completion Dec 2026
Drug: HRS-7058 + SHR-1316; HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy and 11 more · For: Advanced Malignant Tumour
Sites: Beijing, China; Tianjin, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06383871 · 233 participants (planned) · Start Jun 6, 2024 · Primary completion Jun 2026
Drug: HRS-7058 capsule/ HRS-7058 tablet · For: Advanced Malignant Tumour
Sites: Tianjin, China
- The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung CancerNot yet recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07704645 · 180 participants (planned) · Start Aug 2026 · Primary completion Jun 2028
Drug: Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection; Adebrelimab Injection combined with HRS-7058 Capsule · For: Resectable Non-small Cell Lung Cancer
Sites: Shanghai, China
- Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal CancerPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07503639 · 134 participants (planned) · Start Apr 2026 · Primary completion Apr 2028
Drug: SHR-1701; SHR-8068 and 5 more · For: Locally Advanced Colorectal Cancer
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07032077 · 100 participants (planned) · Start Jul 9, 2025 · Primary completion Jun 2027
Drug: HRS-7058 · For: Solid Tumors
Sites: Beijing, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07589569 · 92 participants (planned) · Start Jun 4, 2026 · Primary completion Dec 2028
Drug: HRS-7058 · For: Pancreatic Cancer
Sites: Nanjing, China; Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.